2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 449

The Course of Disability Related to Function of the Upper Extremities in Early Rheumatoid Arthritis over 10 Years of Follow-up
Abstract Number: 450

ACPA-positive versus ACPA-negative Rheumatoid Arthritis: Two Distinct Erosive Disease Entities on Radiography and Ultrasonography
Abstract Number: 451

Persistent and Non-Articular Regional and Widespread Pain Are Common in Early Rheumatoid Arthritis, Impacting Remission Rates and Reflected in Patient Global Scores
Abstract Number: 452

Anti-citrullinated Vimentin Antibodies Are Associated to Early Deterioration of Cortical Bone and Volumetric Bone Mineral Density in Finger Joints in RA-at-risk Patients
Abstract Number: 453

Including Pain, Fatigue and Functionality Regularly in the Assessment of Patients with Early Rheumatoid Arthritis Separately Adds to the Evaluation of Disease Status
Abstract Number: 454

Principal Component Analysis Identifies Unique Sub-Populations in Rheumatoid Arthritis Using a Combination of Serological Biomarkers: A Cross Sectional Study
Abstract Number: 455

Anti-Protein-Arginine Deiminase (PAD) 4 IgA Are Present in the Sera of Rheumatoid Arthritis Patients and Are Associated with Joint Erosion and Biological Treatment Use
Abstract Number: 456

Vitamin D Is Not Associated with Treatment Responses in Patients with Newly Diagnosed Rheumatoid Arthritis
Abstract Number: 457

Serum Myostatin in Patients with Rheumatoid Arthritis and Its Correlations with Body Compositions and the Disease Activity
Abstract Number: 458

The Influence of Mediterranean Diet in Rheumatoid Arthritis: A Monocenter Cross-sectional Study
Abstract Number: 459

The Effects of Erythrocytes and Platelets on Disease Activity in Patients with RA – ANSWER Longitudinal Cohort Study –
Abstract Number: 460

Fertility of Women with Rheumatoid Arthritis: Disease Activity Negatively Correlates with Serum AMH Levels
Abstract Number: 461

Maximal Improvement in Fatigue Lags Behind Achievement of Sustained Remission in Early Rheumatoid Arthritis
Abstract Number: 462

The Endogenous Plasma Small RNAome of Rheumatoid Arthritis
Abstract Number: 463

High-titer Rheumatoid Factor Impacts Real-life Management Outcomes of Rheumatoid Arthtitis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.